|
Avenue Therapeutics ، Inc. (ATXI) DCF تقييم
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Avenue Therapeutics, Inc. (ATXI) Bundle
Simplify Avenue Therapeutics ، Inc. (ATXI) التقييم مع هذه الآلة الحاسبة DCF القابلة للتخصيص! يضم REAL Avenue Therapeutics ، Inc. (ATXI) ومدخلات التنبؤ القابلة للتعديل ، يمكنك اختبار السيناريوهات وكشف القيمة العادلة Avenue Therapeutics ، Inc. (ATXI) في دقائق.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | .0 | -5.2 | .0 | .0 | 4.1 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | 26.3 | 5.2 | 3.7 | 8.0 | 14.5 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -26.3 | -10.4 | -3.7 | -8.0 | -10.5 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 8.7 | 3.1 | 3.8 | 6.7 | 1.8 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | .4 | .2 | .4 | .2 | .4 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | -1.0 | .0 | .0 | -3.0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 1.06 | 1.06 | 1.06 | 1.06 | 1.06 | 1.06 | 1.06 | 1.06 | 1.06 | 1.06 |
| EBITAT | -25.9 | -10.3 | -3.7 | 4.6 | -10.4 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | .7 | -6.3 | .1 | 12.5 | 1.4 | -.4 | .0 | .0 | .0 | .0 |
| WACC, % | 4.97 | 4.97 | 4.97 | 4.97 | 4.97 | 4.97 | 4.97 | 4.97 | 4.97 | 4.97 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | 0 | |||||||||
| Net Debt | -2 | |||||||||
| Equity Value | 1 | |||||||||
| Diluted Shares Outstanding, MM | 0 | |||||||||
| Equity Value Per Share | 9.92 |
What You Will Get
- Editable Forecast Inputs: Easily modify key assumptions (growth %, margins, WACC) to generate various scenarios.
- Real-World Data: Avenue Therapeutics, Inc. (ATXI) financial data pre-loaded to facilitate your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
- Customizable and Professional: A refined Excel model designed to suit your valuation requirements.
- Built for Analysts and Investors: Perfect for evaluating projections, validating strategies, and enhancing efficiency.
Key Features
- Comprehensive DCF Calculator: Offers detailed unlevered and levered DCF valuation models tailored for Avenue Therapeutics, Inc. (ATXI).
- WACC Calculator: Features a pre-built Weighted Average Cost of Capital sheet with adjustable parameters.
- Customizable Forecast Assumptions: Adjust growth rates, capital expenditures, and discount rates as needed.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios specific to Avenue Therapeutics, Inc. (ATXI).
- Dashboard and Visualizations: Graphical outputs present key valuation metrics for straightforward analysis.
How It Works
- Download: Get the pre-built Excel file containing Avenue Therapeutics, Inc. (ATXI) financial data.
- Customize: Modify projections, such as revenue growth, EBITDA %, and WACC.
- Update Automatically: Watch as intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various forecasts and instantly compare results.
- Make Decisions: Leverage the valuation insights to inform your investment approach.
Why Choose This Calculator for Avenue Therapeutics, Inc. (ATXI)?
- Designed for Experts: A sophisticated tool utilized by analysts, CFOs, and healthcare consultants.
- Comprehensive Data: Avenue Therapeutics’ historical and projected financials preloaded for precision.
- Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
- Transparent Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Step-by-step guidance to navigate through the calculations.
Who Should Use This Product?
- Investors: Accurately assess Avenue Therapeutics, Inc. (ATXI)'s fair value prior to making investment choices.
- CFOs: Utilize a high-quality DCF model for financial reporting and analysis related to Avenue Therapeutics, Inc. (ATXI).
- Consultants: Easily customize the template for valuation reports tailored to Avenue Therapeutics, Inc. (ATXI) clients.
- Entrepreneurs: Acquire knowledge on financial modeling practices employed by leading biotech firms like Avenue Therapeutics, Inc. (ATXI).
- Educators: Implement it as a teaching resource to illustrate valuation techniques relevant to Avenue Therapeutics, Inc. (ATXI).
What the Template Contains
- Preloaded ATXI Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.